Abstract:We investigated the efficacy of allogeneic hematopoietic stem cell transplantation (alloHSCT) in pediatric patients with mucopolysaccharidosis (MPS). A retrospective analysis of transplantation data from 34 cases of MPS from the China Children Transplant Group, treated between December 2004 and September 2015, was conducted. Among the 34 cases, 12 cases were type I, 12 were type II, 4 were type IV, 4 were type VI, and 2 were of an unknown type. The median age at transplantation was 3.75 years (range, 1 to 7 years); the median follow-up time was 14 months (range, 2 to 119 months). Eleven patients underwent unrelated cord blood transplantation and 23 underwent peripheral blood stem cell transplantation (4 cases with an HLA-matched sibling donor, 2 cases with an HLA-mismatched related donor, and 17 cases with an unrelated donor). A busulfan-based myeloablative regimen was used as a conditioning regimen. The estimated overall survival at 3 years was 84.8% 6.3% and 91.2% of the patients (31 of 34) achieved full donor chimerism. Twenty-seven children were evaluable and all but 1 (carrier sibling donor; enzyme level improved but failed to reach normal) achieved normal enzyme level after transplantation. The incidence of grades II to IV acute graft-versus-host disease (aGVHD) was 41.1% (14 of 34), wherein the incidence of grades III and IV aGVHD was 11.8% (4 of 34). The incidence of moderate-to-severe chronic graft-versus-host disease was 5.9% (2 of 34). There was a significant difference in the survival rate between children who received transplantation before 2009 and those after 2009 (55.6% versus 95.7%, P=.002); the survival rate was lower in patients with pneumonia before transplantation than in those with no active infection before transplantation (66.7% versus 95.5%, P=.019), and no significant differences in survival rates were observed among children with different disease types, ages at transplantation, donor/graft source, and conditioning regimens. After transplantation, upper-airway obstruction, hepatosplenomegaly, and corneal clouding were significantly improved; hearing and motor function were improved to a certain extent; valvular heart disease was improved in some patients but progressed in others; and short stature and speech skills showed little improvement. AIIoHSCT may save the lives of patients with MPS I, II, IV or VI and could improve quality of life. Pretransplantation pneumonia affects transplantation outcomes. Advances in transplantation protocols and techniques help to improve patient prognosis. Well-matched unrelated donors can also be an ideal donor source. Standardized follow-up and a multidisciplinary team contribute to accurate evaluation of long-term post transplantation outcome and further improve the quality of life of MPS patients. (C) 2016 American Society for Blood and Marrow Transplantation.

Progress of Treatment for Mucopolysaccharidosis

Update of treatment for mucopolysaccharidosis type III (sanfilippo syndrome)

[Treatment of 2 children with mucopolysaccharidosis by allogeneic hematopoietic stem cell transplantation].

Current status and progress of mucopolysaccharidosis type Ⅰ

Molecular Mechanisms in Pathophysiology of Mucopolysaccharidosis and Prospects for Innovative Therapy

Mucopolysaccharidosis Type Ⅱ: a Progress on Molecular Genetics

Allogeneic Hematopoietic Stem Cell Transplantation in Thirty-Four Pediatric Cases of Mucopolysaccharidosis-A Ten-Year Report from the China Children Transplant Group.

Clinical and GUSB Gene Analysis of a Patient with Mucopolysaccharidosis Type Ⅶ and Prenatal Diagnosis for Her Sibling

Progress of glycogen storage disease type Ⅰ

Mucopolysaccharidosis III: Molecular basis and treatment

Long-term Effects of Enzyme Replacement Therapy for Taiwanese Patients with Mucopolysaccharidosis IVA.

Clinical manifestations and genetic mutation analysis of patients with mucopolysaccharidosis type VII in China

Advances in the Research of Molecular Genetics of Alagille Syndrome

Mucopolysaccharidosis Type I: The Importance of Early Diagnosis for Adequate Treatment

One case with hypoglycemic encephalopathy caused by fructose-1,6-bisphosphatase deficiency and novel mutations on FBP1 gene

The Outcome of Allogeneic Hematopoietic Stem Cell Transplantation From Different Donors in Recipients With Mucopolysaccharidosis

Updated Confirmatory Diagnosis for Mucopolysaccharidoses in Taiwanese Infants and the Application of Gene Variants

Iminosugars for the treatment of lysosomal storage disorders

Brain‐targeted stem cell gene therapy corrects mucopolysaccharidosis type II via multiple mechanisms

Research progress on anesthesia for children with mucopolysaccharidosis

[Enzymatic Diagnosis of 47 Cases with Mucopolysaccharidosis].